KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization - Total (2018 - 2023)

TherapeuticsMD (TXMD) has disclosed Depreciation & Amortization - Total for 5 consecutive years, with $100000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation & Amortization - Total changed 0.0% year-over-year to $100000.0, compared with a TTM value of $100000.0 through Sep 2024, changed 0.0%, and an annual FY2023 reading of $100000.0, down 83.33% over the prior year.
  • Depreciation & Amortization - Total was $100000.0 for Q4 2023 at TherapeuticsMD, up from -$27000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $200000.0 in Q2 2022 and bottomed at -$27000.0 in Q2 2023.